Role of Vasoactive Hormone-Induced Signal Transduction in Cardiac Hypertrophy and Heart Failure

Naranjan S Dhalla1, Karina O Mota2, Vijayan Elimban1

  • 1Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Department of Physiology and Pathophysiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R2H 2A6, Canada.

Cells
|May 24, 2024
PubMed

Insights

Vasoactive hormones trigger cardiac hypertrophy and heart failure by increasing cardiac workload and promoting oxidative stress. This leads to cellular damage and impaired heart function, highlighting a key mechanism in cardiovascular disease progression.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Biochemistry

Background:

  • Heart failure is a common outcome of cardiovascular diseases, often preceded by cardiac hypertrophy.
  • Cardiac hypertrophy involves adaptive or maladaptive changes in the heart muscle.

Purpose of the Study:

  • To elucidate the biochemical mechanisms underlying cardiac hypertrophy and its progression to heart failure.
  • To investigate the role of vasoactive hormones and oxidative stress in heart failure development.

Main Methods:

  • Review of proposed biochemical mechanisms.
  • Analysis of signal transduction pathways activated by vasoactive hormones.
  • Examination of the role of oxidative stress in cardiac dysfunction.

Main Results:

  • Vasoactive hormones (catecholamines, angiotensin II, vasopressin, serotonin, endothelins) stimulate cardiomyocyte protein synthesis, leading to hypertrophy.
  • Elevated hormones cause hemodynamic overload, ventricular wall tension, and cardiac remodeling.
  • Prolonged hormone exposure induces oxidative stress via monoamine oxidase and NADPH oxidase, contributing to fibrosis and cardiac dysfunction.

Conclusions:

  • Vasoactive hormones are key drivers of cardiac hypertrophy through hemodynamic overload and signal transduction.
  • Oxidative stress resulting from prolonged hormone exposure critically contributes to the progression of heart failure.
  • Understanding these mechanisms is vital for developing therapeutic strategies for heart failure.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
638
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570